CORCEPT THERAPEUTICS INC 4

Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics Inc. (CORT), exercised 20,305 stock options at $8.27 and sold 20,305 shares of common stock at about $114.70 per share under a 10b5-1 plan, leaving 9,755 shares owned directly plus substantial indirect holdings.

On August 3, 2026, Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics Inc., exercised 20,305 stock options at an exercise price of $8.27 per share, converting them into 20,305 shares of common stock, and on the same day sold 20,305 shares of common stock at a weighted average price of $114.7045 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 9,755 shares of common stock held directly. In addition to his direct holdings, he has multiple indirect holdings through various entities and trusts, including 5,147 shares in the Sean and Molly Maduck Living Trust, 20,570 shares in MMM 2025, LLC, 40,000 shares in the SNM 2025 Grantor Retained Annuity Trust, 34,000 shares in the SNM 2026 Grantor Retained Annuity Trust, and 10,000 shares in Duckhill Capital, LLC. His post-transaction direct holdings also include 2,228 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their respective 2025–2026 grant dates, contingent on continued service, and his options exercised on this date were reported as fully exercisable. The sale price range for the disposition was between $114.49 and $115.00 per share, generating an estimated gross sale value of roughly $2.33 million against an aggregate exercise cost of about $0.17 million, resulting in a sizable spread while largely maintaining significant indirect exposure through trust and entity holdings.

Filing Facts

CIK

1088856

Ticker

CORT

Form

4

Source Type

fda

Accession

0001193125-26-335617

Alert Tier

6